| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 06 Nov 2026 |
8-K: Results of Operations and Financial Condition
Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38 |
| 30 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Jerh Collins to Retire Following Four Years of Leadership at Moderna |
| 01 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE dated as of September 1, 2026 between MODERNA, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, ... |
| 31 Jul 2026 |
8-K: Results of Operations and Financial Condition
Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97) |
| 08 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience |
| 11 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
Section 8 of Article VI of the Second Amended and Restated By-laws of the Corporation (the “By-laws”) is hereby amended and restated in its entirety as follows: |
| 01 May 2026 |
8-K: Results of Operations and Financial Condition
Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets |
| 05 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutu... |
| 13 Feb 2026 |
8-K: Results of Operations and Financial Condition
Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11) |
| 11 Feb 2026 |
8-K: Regulation FD Disclosure; Other Events
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010 |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call |
| 05 Jan 2026 |
8-K: Regulation FD Disclosure
Moderna navigated a difficult environment in the U.S. in 2025. In this complex context, we focused on what we could control: operational execution, scientific progress and disciplined financial management. Our Mission—to deliver the grea... |
| 24 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
CERTAIN SUBSIDIARIES OF THE BORROWERFROM TIME TO TIME PARTY HERETO,as Guarantor Subsidiaries, |
| 20 Nov 2025 |
8-K: Regulation FD Disclosure
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 |
| 13 Nov 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On November 12, 2025, Moderna, Inc. (the “Company”) held its previously announced Special Meeting of Shareholders (the “Special Meeting”), at which a quorum was present. The final voting results for the Special Meeting are as follows: |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) |
| 01 Aug 2025 |
8-K: Results of Operations and Financial Condition
Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) |
| 05 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On April 30, 2025, the Company held its previously announced 2025 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. The final voting results for the Annual Meeting are as follows: |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition
Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52) |
Loading...